Tagged with Global

USA John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in the long-term.   Strategic failure begins when you turn things over to technologists.   “My 18-year-old daughter, Caroline, responded quickly…

Global Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth of potential breakthrough assets in its pipeline, product launch strategies, and the post-COVID industry of tomorrow.   Since I joined in 2011, it feels as if my time with Sanofi…

Roche Swiss giant Roche tops Pharmaceutical Executive’s 2020 list of the world’s biggest pharma companies, up from second place in 2019 and third in 2018. Though its best-selling drugs are soon to face biosimilar competition, Roche’s diverse portfolio has ensured that it can continue to drive future sales growth. The firm…

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

Merck Teresa Rodó gives an overview of her role overseeing the development, manufacturing, supply, and quality of all of Merck’s biotech and pharmaceutical medicines and medical devices. Rodó also explains how the company has been able to withstand the supply chain challenges posed by the COVID-19 pandemic, and why Merck is…

AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19.   Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…

Coronavirus The BIO International Convention was held digitally in June 2020, bringing together over 7,000 participants from around the world. In an R&D-focused session titled “Whiplash! How Covid-19 Will Radically Change Biomedical R&D Across the Globe,” moderator Andy Marshall of Nature Biotechnology brought together experts in biotech, pharma innovation and research.…

Global ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on leadership. Click here to read the full report.   The first impression listening to…

Global ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on strategy. Click here to read the full report.   Compared to other businesses,…